Optomed Oyj Class A · OMXHEX:OPTOMED
Optomed Oyj Class A — Nordic American Life Science Conference 2022
7 slides from Optomed Oyj Class A's conference presentation, Dec 1, 2022
Slide 1: Enabling Eye Screening for All
Optomed Enabling Eye Screening for All Nordic American Life Science Conference 2022 Seppo Kopsala, CEO
Slide 2: Megatrends driving the growth of eyecare market
Megatrends driving the growth of eyecare market Aging population Diabetes growing AI Prevalence of serious eye Technological advances in Diabetic Retinopathy (causing vision loss) diseases (causing vision artificial intelligence enable affects ~35% of all diabetics but can be loss) increase strongly
Slide 3: We provide unique handheld fundus cameras with AI for screening of blinding eye diseases
We provide unique handheld fundus cameras with AI for screening of blinding eye diseases Optomed’s handheld Traditional equipment …together with AI camera… • Large initial investments • Cost efficient • Saves eye doctor • Space constrains • For the use of all healthcare resources and lowers • For pr
Slide 4: Team in the US since 2020
Team in the US since 2020 Established 2004, HQ and product development in Oulu, Finland Revenue 15 MEUR (2021) Over 60 distributors in 50 countries; several OEM partners Several AI partnerships e.g.. AEYE Health Ltd, Eyenuk Inc, EyRIS Pte. Ltd. Office Outsourced manufacturing 55+ international paten
Slide 5: Significant recurring revenue opportunity in the US
Significant recurring revenue opportunity in the US Screening of diabetic retinopathy is starting to move to primary care Complete Solution Recurring Revenue Model Customer Benefits Newly established From product sales to Solution leased, not complete screening No initial investments reimbursement s
Slide 6: Extensive clinical trials completed in February 2022 in the US
Extensive clinical trials completed in February 2022 in the US 91.9% 93.6% 99+% Only a single sensitivity specificity imageability image per eye Optomed Aurora AEYE solution for screening of diabetic retinopathy Seeking FDA clearance for the solution in near future CAUTION - Investigational device.
Slide 7: Thank You
Thank You Seppo Kopsala, CEO seppo.kopsala@optomed.com Optomed Plc. Yrttipellontie 1, 90230 Oulu, Finland Tel: +358 20 741 3380 • investors@optomed.com www.optomed.com
Optomed — Nordic American Life Science Conference 2022 on 6ix